Jules Eggli (COO) joined the team in 2023 to complement his business experience in guiding  Ai.Qimia’s founding and market positioning. Mr. Eggli graduated with a degree in Economics at San José State University in Silicon Valley before continuing his work at both multinationals and start-ups. After  running the International Distribution and Sales department at a major New York City-based media company, Mr. Eggli spent several years in Switzerland working in sales, marketing and international licensing. He most recently was head of business development at Largo.ai, an EPFL spin-off that brings next-generation storytelling tools to the audiovisual industry using artificial intelligence.

Dr. Peter Jarowski (CEO) is an expert in organic theory and the application of computational methods in mechanism and thermochemistry. Throughout his career in experimental organic synthesis he used quantum theory to accelerate research and to help elucidate fundamentals. Ai.Qimia integrates Dr. Jarowski’s deep knowledge of theory with his understanding of the needs of experimental chemists to achieve reliable predictions without the hassle of the technical aspects of computational chemistry.

Willi Studer (HR) is the founder of Proviatus Ltd, a Consulting firm specialized in Change and Transition Management, Executive Coaching and HR Development. He has a strong business background with both project management expertise and people management experience. Willi holds a Master of Law degree of the University of Zurich, and a Diploma in Organizational Psychology from Insead, France (Consulting and Coaching for Change). He is of Swiss and French nationality who speaks fluent German, French, English, and Swiss German.

Dr. Gilbert Lassalle spent much of his careeer in leadership roles at Evotec wit his last position in 2022 as SVP, Head of Medicinal Chemistry France. He was a strong advocate of the Evotec MedChem EVOlution strategy including use of predictive in silico tools to aid his team of over 40 scientists involved in Synthetic and Medicinal Chemistry, Prior to his work at Evotec he was Section Leader at Sanofi R&D, DPU Early to Candidate and Lab head at Synthelabo, cardiovascular dpt. Has made significant efforts to implement novel technologies such as parallel synthesis and micro-flow chemistry.
Co-author of 51 patent(s) (applications), 17 publications. Contributions to various development candidates : 1 in phase II, 4 in phase I, 10 in preclinical development.

Dr. Warren Wade recently founded Informative Chemistry Solutions in 2020 to apply his over 25 years’ experience in cheminformatics and medicinal chemistry for difficult projects in Drug Discovery and related chemistry intensive fields. Previously at BioBlocks, Inc, Dr. Wade was the main inventor of the Leap-to-Lead platform that applied chemistry innovation, cheminformatics and next generation FBLD to lead discovery. He also spent 7 years at Neurocrine Biosciences as a Director of Medicinal Chemistry where he advanced two small molecule candidates for Investigational New Drug (IND) filings. One candidate, ORILISSA (elagolix) was approved for endometriosis in the US during 2018. Prior to this, Dr. Wade spent 8 years at Abbott where he was involved in developing the Company’s combinatorial chemistry informatics to parallel synthesis, solid phase synthesis and medicinal chemistry. Dr. Wade is an author of over 25 publications and a co-inventor on more than 20 issued US patents. He has a Ph.D. in Bioorganic Chemistry from the California Institute of Technology (Caltech) and a BA in Chemistry from Cornell University.